Neurosense Therapeutics Ltd. NRSN 深 沪
已收盘 01-09 16:00:00 美东时间
1.07
+0.132
+14.07%
华盛通- 最 高1.10
- 今 开0.93
- 成交量 45.12万股
- 最 低 0.93
- 昨 收 0.938
- 总市值 3161.96万
- 52周最高 2.60
- 市盈率 静 --
- 换手率 1.53%
- 52周最低 0.6801
- 委 比 -99.83%
- 总股本 2955.10万
- 历史最高 8.18
- 量 比 2.05
- 振 幅 18.12%
- 历史最低 0.40
- 每 手 1
- 风险率 0.38%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB
Alzheimer's Clinical and Biomarker Outcomes Expected in Q1 2026 CAMBRIDGE, Mass., Jan. 8, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical sta...
01-08 21:45
NeuroSense Therapeutics' Analysis From Phase 2 NST-AD-001 Trial Of PrimeC Combination In Alzheimer's Demonstrates Favorable Tolerability For PrimeC
NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today reported completion of the safety
2025-12-22 22:20
NeuroSense Completes Data Collection for Alzheimer’s Trial
Neurosense Therapeutics Ltd. ( ($NRSN) ) just unveiled an update. NeuroSense Th...
2025-12-08 21:27
NeuroSense Therapeutics Resumes Regulatory Push in Canada for ALS Drug PrimeC After Productive Talks
NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that following a
2025-12-04 20:32
美股大行评级 | 摩根大通上调百度至"超配"，目标价升至188美元！Navan获多家机构首予"买入"评级，目标价最高30美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从4美元升至9美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从32美元升至38美元
2025-11-25 10:27
FDA Completes Review Of IND Amendment Application And Authorizes NeuroSense To Initiate Pivotal Phase 3 Clinical Trial For Evaluation Of PrimeC, For ALS Treatment
NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the U.S. Food and
2025-11-24 22:59
Neurosense Therapeutics Announces Phase 2b PARADIGM Study Results For PrimeC Showing Statistically Significant Reductions In Multiple Micrornas Linked To Alzheimer's Disease
NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced new positive findings
2025-10-06 21:07
NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers
CAMBRIDGE, Mass., Oct. 6, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe ...
2025-10-06 21:00
NeuroSense Reports Positive Initial Results for Alzheimer’s Drug Candidate
Neurosense Therapeutics Ltd. ( ($NRSN) ) has issued an announcement. On Septemb...
2025-09-11 02:59
NeuroSense Reports Phase 2 RoAD Trial Results, Says PrimeC Boosts Brain Connectivity In Alzheimer's, Shows Favorable Safety Profile
Initial Phase 2 RoAD trial results demonstrate improvements in brain-cell connectivity and health, with a favorable safety profileCAMBRIDGE, Mass., Sept. 10, 2025 /PRNewswire/ -- NeuroSense Therapeutics
2025-09-11 02:32
